galectin-slider-v1-670x220

News

Galectin Therapeutics to Present at Rodman & Renshaw 18th Annual Global Investment Conference

August 31, 2016 | Press Release

Galectin Therapeutics Announces Results From 12-Week Extension of Phase 2a Psoriasis Clinical Trial

August 25, 2016 | Press Release

Galectin Therapeutics Reports Second Quarter 2016 Financial Results and Provides Business Update

August 9, 2016 | Press Release

Highlights

What are galectins and why are they a good target for the treatment of NASH?

Are you conducting clinical trials with GR-MD-02? What results have you seen so far?

Why did you choose to become the CEO of Galectin Therapeutics?

Why is fatty liver disease called "the hidden epidemic?"

What is fibrosis and what role does it play in chronic diseases such as NASH?

Galectin Therapeutics, Inc.

NASDAQ: GALT

Financial Tear Sheet
Filings & Reports

Stock price updates every 30 minutes.

Corporate Snapshot

Subscribe

Sign up for our latest updates